Föreläsningar och seminarier

Seminarium - VSV-Ebola Virus as pre-and post-exposure treatment for Ebola virus infections

This page in English
2016-05-2713:00 to 15:00 Föreläsningssal 4Y, Alfred Nobels Allé 8, plan 4Campus Huddinge

Seminars in Clinical Microbiology, Department of Laboratory Medicine

"VSV-Ebola Virus as pre-and post-exposure treatment for Ebola virus infections"

Dr. Andrea Marzi
National Institute2 of Health (NIH), USA


Science. 2015 Aug 14;349
The latest Ebola virus (EBOV) epidemic spread rapidly through Guinea, Sierra Leone, and Liberia, creating a global public health crisis and accelerating the assessment of experimental therapeutics and vaccines in clinical trials. One of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), a live-attenuated vector with marked preclinical efficacy. Here, we provide the preclinical proof that VSV-EBOV completely protects macaques against lethal challenge with the West African EBOV-Makona strain. 

Contact person: Ali Mirazimi